Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Director Charles O’keeffe acquired 10,000 shares of the stock on the open market in a transaction that occurred on Wednesday, February 5th. The shares were purchased at an average cost of $1.81 per share, for a total transaction of $18,100.00. Following the completion of the transaction, the director now directly owns 177,126 shares of the company’s stock, valued at approximately $320,598. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.78 on Friday. Catalyst Pharmaceutical Partners has a one year low of $0.41 and a one year high of $3.65. The stock’s 50-day moving average is $2.00 and its 200-day moving average is $1.96. The company’s market cap is $96.4 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last released its earnings data on Thursday, November 14th. The company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.07). Analysts expect that Catalyst Pharmaceutical Partners will post $-0.32 EPS for the current fiscal year.
A number of research firms have recently commented on CPRX. Analysts at Aegis reiterated a “buy” rating on shares of Catalyst Pharmaceutical Partners in a research note to investors on Wednesday, January 8th. Analysts at Zacks downgraded shares of Catalyst Pharmaceutical Partners from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, November 19th. They now have a $1.90 price target on the stock.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
Receive News & Ratings for Catalyst Pharmaceutical Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners and related companies with Analyst Ratings Network's FREE daily email newsletter.